Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Articles|July 29, 2022
- July 2022
- Volume 88
- Issue 7
Pet Peeves: July 2022
Brought to you by The Sassy Pharmacist
Advertisement
Shrouded in Mystery
After you ring out the prescriptions and give to the patient they ask “so what did I get here?”
DIY
Patients who ask the pharmacist to go online to schedule a COVID-19 test or vaccine for them.
Not a Refill Request
The pharmacist sends the physician the prior authorization rejection and then gets a script for the same thing.
What’s Bothering You?
Bossy patients, abandoned prescriptions, drive-through demands? We want to know! Send your pet peeves to cmollison@pharmacytimes.com. We’ll share them here and online.
Articles in this issue
about 4 years ago
National Practitioner Data Bank Aims to Reduce Malpracticeabout 4 years ago
July 2022: Generic Product Newsabout 4 years ago
Pharmacists Can Help Manage Patients With Parkinson Diseaseabout 4 years ago
Quviviq From Idorsia Pharmaceuticalsabout 4 years ago
OTC Case Studies: Rhinitisabout 4 years ago
July 2022: Rx Product Newsabout 4 years ago
Know Your Salary Rangeabout 4 years ago
Help Patients Use Inhalers Properlyabout 4 years ago
Illinois Legislature Empowers Pharmacistsabout 4 years ago
Board’s Licensure Revocations Are Upheld on AppealAdvertisement
Related to this article
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
5